Drug Resistance

Early detection system of drug resistance mutations in myeloid leukemia studied

Published in Gene Therapy Weekly, July 28th, 2005

Transgenomic Inc. (TBIO) announced the publication of a study demonstrating the ability of its Wave System to enable detection of mutations in the BCR-ABL gene that are associated with development of resistance to imatinib therapy in chronic myeloid leukemia (CML) patients.

In 3 out of 19 patients harboring BCR-ABL mutations, the mutations were detectable 1-2 months from the onset of therapy only by denaturing HPLC performed with the Wave system, but were not detectable by direct DNA sequencing. Since all but 4 patients with mutations had sustained hematologic responses to imatinib at the time of mutation detection, early mutation screening may identify patients at risk...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2005-07-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry